background: the liver is the corner stone in lipid metabolism, free fatty acid uptake, synthesizing, storing, and exporting lipids, non-alcoholic fatty liver disease (NAFLD), develops if there is any interruption or derangement in lipid metabolism. fatty acid synthetase (FAS) is the major enzyme in lipogenesis, and its circulating level is biomarker of metabolically demanding human diseases.

aim of the work: to evaluate the level of circulating FAS in NAFLD patients and to correlate it to serum lipid parameters

conclusion: elevated levels of circulating FAS can be considered as a biomarkers of fatty liver disease